Pivotal Therapeutics Inc. reported audited consolidated earnings results for the first quarter ended March 31, 2014. For the period, the company reported a loss of CAD 1,613,667, or CAD 0.02 per common share. This included CAD 508,952 in non-cash expenses related to the awarding of stock options in the period.

In last year's first quarter, the loss was CAD 783,436, or CAD 0.01 per common share.